Predicting Response to Platin Chemotherapy Agents with Biochemically-inspired Machine Learning
By
Eliseos J Mucaki,
Jonathan Z.L Zhao,
Dan Lizotte,
Peter K Rogan
Posted 11 Dec 2017
bioRxiv DOI: 10.1101/231712
(published DOI: 10.1038/s41392-018-0034-5)
Selection of effective genes that accurately predict chemotherapy response could improve cancer outcomes. We compare optimized gene signatures for cisplatin, carboplatin, and oxaliplatin response in the same cell lines, and respectively validate each with cancer patient data. Supervised support vector machine learning was used to derive gene sets whose expression was related to cell line GI50 values by backwards feature selection with cross-validation. Specific genes and functional pathways distinguishing sensitive from resistant cell lines are identified by contrasting signatures obtained at extreme vs. median GI50 thresholds. Ensembles of gene signatures at different thresholds are combined to reduce dependence on specific GI50 values for predicting drug response. The most accurate models for each platin are: cisplatin: BARD1, BCL2, BCL2L1, CDKN2C, FAAP24, FEN1, MAP3K1, MAPK13, MAPK3, NFKB1, NFKB2, SLC22A5, SLC31A2, TLR4, TWIST1; carboplatin: AKT1, EIF3K, ERCC1, GNGT1, GSR, MTHFR, NEDD4L, NLRP1, NRAS, RAF1, SGK1, TIGD1, TP53, VEGFB, VEGFC; oxaliplatin: BRAF, FCGR2A, IGF1, MSH2, NAGK, NFE2L2, NQO1, PANK3, SLC47A1, SLCO1B1, UGT1A1. TCGA bladder, ovarian and colorectal cancer patients were used to test cisplatin, carboplatin and oxaliplatin signatures (respectively), resulting in 71.0%, 60.2% and 54.5% accuracy in predicting disease recurrence and 59%, 61% and 72% accuracy in predicting remission. One cisplatin signature predicted 100% of recurrence in non-smoking bladder cancer patients (57% disease-free; N=19), and 79% recurrence in smokers (62% disease-free; N=35). This approach should be adaptable to other studies of chemotherapy response, independent of drug or cancer types.
Download data
- Downloaded 1,063 times
- Download rankings, all-time:
- Site-wide: 18,018
- In pharmacology and toxicology: 99
- Year to date:
- Site-wide: 69,264
- Since beginning of last month:
- Site-wide: None
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!